Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) shared Wednesday positive results from its extended stability testing, which showed unparalleled stability for bottled CBD drinks made using its technology.
The Kelowna, British Columbia-based company’s patented DehydraTECH cannabidiol (CBD) nano-emulsification formulation and processing techniques, ensured the tested beverages maintained their CBD content, which was verified at 93.4% of target potency one year after production. The drinks also had “excellent microbial purity over this period,” said the company.
In addition, the DehydraTECH ready-to-drink (RTD) beverages were tested for content uniformity and homogeneity of CBD distribution and demonstrated “less than 1% variability” in CBD potency in fractions sampled from the top, middle, and bottom of the drink without physical mixing.
READ: Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program
"I love reminding people that Lexaria's first patent was awarded in 2016 for CBD-infused beverages and consumable liquids," Lexaria CEO Chris Bunka said in a statement.
"Our technology was working in cannabinoid beverages years before the big cannabis companies started spending hundreds of millions of dollars trying to figure it out," he added.
In February last year, Lexaria made patented DehydraTECH-powered CBD-based nano-emulsions for Nic's Beverages, which owns the popular Nic's Cold Brew brand. It has been subjecting samples from the commercial bottling run to long-term stability testing that has shown “average potency of 93.4% after one year, complete uniformity, and no microbial growth.” This testing will continue until the “formulation no longer remains stable,” added the company.
Nic's Beverages CEO John Goodpasture said his company is “incredibly happy with the world-class results” the beverage maker has experienced using DehydraTECH.
"The coffee flavour and aroma experience are exceptional from the moment you open the bottle and remain so one year later," added Goodpasture.
Beverages containing cannabinoids often need to be shaken prior to use and tend to degrade over time, sometimes dramatically. There have been reports of beverages sold that contain only a tiny fraction of the CBD listed on the product label, whether due to inadequate manufacturing techniques, or time decay.
In a nutshell, Lexaria's data demonstrate “exceptional effectiveness” in integrating CBD into RTD beverages in a stable and homogenously distributed manner.
DehydraTECH drug delivery technology
Separately, Lexaria's DehydraTECH technology has been clinically verified to deliver a “significantly higher fraction of CBD” to consumers' blood circulation in a shorter period. The company’s proprietary DehydraTECH drug delivery technology improves the way active pharmaceutical ingredients enter the bloodstream by promoting healthier oral ingestion.
Most importantly, the technology can be applied to different ingestible product formats embracing foods, beverages, oral suspensions, tablets and capsules.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive